• 21 March 2018

    Pfizer’s rituximab biosimilar edges closer to approval

    Pfizer’s rituximab biosimilar candidate, PF-05280586, edged closer towards approval on January 24, 2018, when the company announced positive top-line results in a Phase III trial in follicular lymphoma (FL).

  • 19 March 2018

    Digital health: a new direction for neurology

    Recent years have shown a large increase in investment towards digital health, a multifaceted segment in the industry that can combine software-based therapies into different aspects of the drug development...

  • 15 March 2018

    2018 is the year for making strategic alliances in DMD

    Duchenne Muscular Dystrophy (DMD) is a rare neuromuscular degenerative disease that affects 15 in every 100,000 males (CDC, 2018). There is currently no effective therapy to treat the disease. However,...

  • 14 March 2018

    Blockbuster oncology deal for Merck and Eisai

    On 7 March, Merck completed a major strategic collaboration for the global co-development and co-commercialisation of Eisai oncology drug Lenvima (lenvatinib mesylate) worth up to $5.76B.